Blood test could help to accelerate brain cancer diagnosis

October 09, 2019

A blood test which could help to accelerate the diagnosis of brain cancer has been developed in research led at the University of Strathclyde.

The patented technology uses infrared light to produce a "bio-signature" of a blood sample and applies artificial intelligence to check for the signs of cancer.

This research is being commercialised by ClinSpec Diagnostics Limited, an award-winning company spun out from the University in February 2019. The work has now been published in the journal Nature Communications, and also involved clinicians at the Western General Hospital in Edinburgh, the University of Liverpool and the Walton NHS Foundation Trust in Liverpool.

Dr Matthew J. Baker, Reader in Strathclyde's Department of Pure and Applied Chemistry and Chief Scientific Officer with ClinSpec Diagnostics, led the study. He said: "This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumours in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services."

Dr Holly Butler, Research and Development Director with ClinSpec Diagnostics, said: "The results presented are the beginning of a clinical roadmap of studies, that aim to bring the technology through regulatory approval, and ultimately to provide patients with rapid access to diagnosis and treatment.

Dr Paul Brennan, Senior Clinical Lecturer and Consultant Neurosurgeon at the University of Edinburgh, a partner in the study, said: "Diagnosing brain tumours is difficult, leading to delays and frustration for lots of patients. The problem is that symptoms of brain tumour are quite non-specific, such as headache, or memory problems. It can be difficult for doctors to tell which people are most likely to have a brain tumour.

"With this new test, we have shown that we can help doctors quickly identify which patients with these non-specific symptoms should be prioritised for urgent brain imaging. This means a more rapid diagnosis for people with a brain tumour, and quicker access to treatment."

The Brain Tumour Charity ambassador Hayley Smith, whose husband Matthew is currently living with a glioblastoma brain tumour is backing this research. They learned in July 2016, three weeks after Matthew's surgery, that his tumour was a grade 4 glioblastoma.

West-Lothian-based Hayley said: "We urgently need to find new treatments and ultimately a cure as more and more people are being diagnosed with this devastating disease.

"It is very encouraging to hear that this blood test can lead to a quicker diagnosis for brain cancer. Matthew's doctors believe that his brain tumour was slowly growing for around 14 years but only started presenting symptoms that could be linked to a brain tumour around six weeks before he ended up in A and E following a seizure. Initially these symptoms had been misdiagnosed as a migraine- had this new test been available it might have been spotted earlier.

"Scotland now has research teams from all over the world and all are experts in their fields. It's so promising to know that we have the best of the best looking into quicker diagnosis and new treatments.

"This kind of test will be vital to patients, helping people to get the correct diagnosis quicker which ultimately will help people to get the urgent medical care that they need."

Patients with brain cancer frequently present with non-specific symptoms and the final cancer diagnosis can be time-consuming. The researchers have analysed samples from a prospective cohort of 104 patients, they found that the blood test could distinguish patients with brain cancer from healthy individuals correctly 87% of the time.

These findings suggest that this approach may be useful to doctors in helping to prioritise patients needing brain scans in order to diagnose tumours. While the proposed system does not offer an absolute diagnosis, it could play a significant role in the diagnostic process as a triage tool.
-end-
The study received funding from the Scottish Enterprise High Growth Spinout Program and the Engineering and Physical Sciences Research Council (EPSRC).

University of Strathclyde

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.